943757-74-2

Basic information

• Product Name: 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine
• Synonyms: 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine;2-(4-methyl-1-piperazinyl)-5-pyrimidinamine
• CAS NO: 943757-74-2
• Molecular Formula: C₉H₁₅N₅
• Molecular Weight: 193.2489
• Mol File: 943757-74-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 386.316ºC at 760 mmHg
• Flash Point: 187.437ºC
• Appearance: /
• Density: 1.197g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.37±0.42(Predicted)
• CAS DataBase Reference: 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine(943757-74-2)
• EPA Substance Registry System: 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine(943757-74-2)

Safety Data

• Hazardous Substances Data: 943757-74-2(Hazardous Substances Data)

Usage

General Description

2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine is a chemical compound that belongs to the class of pyrimidine derivatives. It consists of a pyrimidine ring with an attached piperazine group and a methyl substituent. 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine has potential therapeutic properties and has been studied for its biological activities, including its antiviral and anticancer effects. It may also be used as a building block in the synthesis of other pharmaceutical compounds. The specific properties and potential applications of 2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine make it a valuable compound for further research and development in the fields of medicine and pharmacology.

InChI:InChI=1/C9H15N5/c1-13-2-4-14(5-3-13)9-11-6-8(10)7-12-9/h6-7H,2-5,10H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 943749-60-8 2-(4-methylpiperazin-1-yl)-5-nitropyrimidine 

Relevant articles and documents

Discovery and in Vivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor

Cathepsin C (Cat C) participates in inflammation and immune regulation by affecting the activation of neutrophil serine proteases (NSPs). Therefore, cathepsin C is an attractive target for treatment of NSP-related inflammatory diseases. Here, the complete discovery process of the first potent "non-peptidyl non-covalent cathepsin C inhibitor"was described with hit finding, structure optimization, and lead discovery. Starting with hit 14, structure-based optimization and structure-activity relationship study were comprehensively carried out, and lead compound 54 was discovered as a potent drug-like cathepsin C inhibitor both in vivo and in vitro. Also, compound 54 (with cathepsin C Enz IC50 = 57.4 nM) exhibited effective anti-inflammatory activity in an animal model of chronic obstructive pulmonary disease. These results confirmed that the non-peptidyl and non-covalent derivative could be used as an effective cathepsin C inhibitor and encouraged us to continue further drug discovery on the basis of this finding.

4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)

The cyclin-dependent kinases (CDKs), as complexes with their respective partners, the cyclins, are critical regulators of cell cycle progression. Because aberrant regulations of CDK4/cyclin D1 lead to uncontrolled cell proliferation, a hallmark of cancer, small-molecule inhibitors of CDK4/cyclin D1 are attractive as prospective antitumor agents. The series of 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-dione derivatives reported here represents a novel class of potent inhibitors that selectively inhibit CDK4 over CDK2 and CDK1 activities. In the headpiece of the 4-(phenylaminomethylene) isoquinoline-1,3(2H,4H)-dione, a basic amine substitutent is required on the aniline ring for the CDK4 inhibitory activity. The inhibitory activity is further enhanced when an aryl or heteroaryl substituent is introduced at the C-6 position of the isoquinoline-1,3(2H,4H)-dione core. We present here SAR data and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.